Dosing & Uses
Dosage Forms & Strengths
capsule
- 140mg (equivalent to 84.5mg [6.93mEq] elemental magnesium)
tablet
- 400mg (equivalent to 240mg [20mEq] elemental magnesium)
Recommended Daily Intake (Elemental Mg)
Females
- 19-30 yr: 310 mg/day PO
- 19-30 yr (pregnant): 350 mg/day PO
- >31 yr: 320 mg/day PO
- >31 yr (pregnant): 360 mg/day PO
Males
- 19-30 yr: 400 mg/day PO
- >31 yr: 420 mg/day PO
Magnesium Supplementation
Tablet (Mag-Ox): 1-2 tablets PO qDay
Capsule (Uro-Mag): 1-5 capsules PO qDay
Antacid
Tablet (Mag-Ox): 1 tablet PO qDay or q12hr; not to exceed 2 tablets/day
Renal Impairment
CrCl <30 mL/min: Caution; monitor for hypermagnesemia
Administration
Take with food
Dosage Forms & Strengths
capsule
- 140mg (equivalent to 84.5mg [6.93mEq] elemental magnesium)
tablet
- 400mg (equivalent to 240mg [20mEq] elemental magnesium)
Recommended Daily Intake (Elemental Mg)
1-3 years: 80 mg/day PO
4-8 years: 130 mg/day PO
9-13 years: 240 mg/day PO
14-18 years
- Females: 360 mg/day PO
- Pregnant females: 400 mg/day PO
- Males: 410 mg/day PO
Renal Impairment
CrCl <30 mL/min: Caution; monitor for hypermagnesemia
Administration
Take with food
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (12)
- atazanavir
magnesium oxide will decrease the level or effect of atazanavir by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Atazanavir solubility decreases as pH increases. Reduced plasma concentrations of atazanavir are expected if antacids or buffered medications are coadministered. Administer atazanavir 2 hr before or 1 hr after these medications.
- baloxavir marboxil
magnesium oxide will decrease the level or effect of baloxavir marboxil by cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted.
- demeclocycline
magnesium oxide decreases levels of demeclocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- dolutegravir
magnesium oxide will decrease the level or effect of dolutegravir by cation binding in GI tract. Avoid or Use Alternate Drug. Administer dolutegravir 2 hr before or 6 hr after taking medications containing polyvalent cations
- doxycycline
magnesium oxide decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- eltrombopag
magnesium oxide decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours.
- infigratinib
magnesium oxide will decrease the level or effect of infigratinib by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. If use with an acid-reducing agent cannot be avoided, administer infigratinib 2 hr before and after administration of a locally-acting antacid.
- minocycline
magnesium oxide decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- oxytetracycline
magnesium oxide decreases levels of oxytetracycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- ponatinib
magnesium oxide decreases levels of ponatinib by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- sotorasib
magnesium oxide will decrease the level or effect of sotorasib by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. If use with an acid-reducing agent cannot be avoided, administer sotorasib 4 hr before or 10 hr after administration of a locally-acting antacid.
- tetracycline
magnesium oxide decreases levels of tetracycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
Monitor Closely (35)
- acalabrutinib
magnesium oxide decreases levels of acalabrutinib by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Acalabrutinib solubility decreases with increasing gastric pH. Separate dosing by at least 2 hr between administration of antacids and acalabrutinib.
- bictegravir
magnesium oxide will decrease the level or effect of bictegravir by cation binding in GI tract. Modify Therapy/Monitor Closely. Bictegravir can be taken under fasting conditions 2 hr before antacids containing Al, Mg, or Ca. Routine administration of bictegravir simultaneously with, or 2 hr after, antacids containing Al, Mg, or Ca is not recommended.
- bosutinib
magnesium oxide decreases levels of bosutinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Bosutinib displays pH-dependent solubility; may use short-acting antacids with administration separated by 2 hr.
- budesonide
magnesium oxide decreases effects of budesonide by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Enteric-coated budesonide dissolves at pH >5.5. Also, dissolution of extended-release budesonide tablets is pH dependent. Coadministration with drugs that increase gastric pH may cause these budesonide products to prematurely dissolve, and possibly affect release properties and absorption of the drug in the duodenum.
- cabotegravir
magnesium oxide will decrease the level or effect of cabotegravir by cation binding in GI tract. Modify Therapy/Monitor Closely. Administer antacid products at least 2 hr before or 4 hr after taking oral cabotegravir.
- chloroquine
magnesium oxide will decrease the level or effect of chloroquine by cation binding in GI tract. Use Caution/Monitor. Separate doses by at least 4 hr
- ciprofloxacin
magnesium oxide decreases levels of ciprofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- crizotinib
magnesium oxide decreases levels of crizotinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that elevate the gastric pH may decrease the solubility of crizotinib and subsequently reduce its bioavailability. However, no formal studies have been conducted. .
- dabrafenib
magnesium oxide will decrease the level or effect of dabrafenib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that alter upper GI tract pH (eg, PPIs, H2-blockers, antacids) may decrease dabrafenib solubility and reduce its bioavailability
- deferiprone
magnesium oxide decreases levels of deferiprone by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Deferiprone may bind polyvalent cations (eg, iron, aluminum, and zinc), separate administration by at least 4 hr between deferiprone and other medications (eg, antacids), or supplements containing these polyvalent cations.
- delafloxacin
magnesium oxide will decrease the level or effect of delafloxacin by cation binding in GI tract. Modify Therapy/Monitor Closely. Oral delafloxacin form chelates with alkaline earth and transition metal cations. Administer oral delafloxacin at least 2 hr before or 6 hr after these agents.
- elvitegravir
magnesium oxide will decrease the level or effect of elvitegravir by cation binding in GI tract. Modify Therapy/Monitor Closely. Elvitegravir plasma concentrations are lower with antacids due to the formation of ionic complexes in the GI tract and not due to changes in gastric pH; separate dose from antacid by at least 2 hr
- elvitegravir/cobicistat/emtricitabine/tenofovir DF
magnesium oxide decreases levels of elvitegravir/cobicistat/emtricitabine/tenofovir DF by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate administration from antacids by 2 hr.
- fleroxacin
magnesium oxide decreases levels of fleroxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- gefitinib
magnesium oxide decreases levels of gefitinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Separate gefitinib and antacid doses by at least 6 hr.
- gemifloxacin
magnesium oxide decreases levels of gemifloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- ledipasvir/sofosbuvir
magnesium oxide decreases levels of ledipasvir/sofosbuvir by Other (see comment). Use Caution/Monitor. Comment: Ledipasvir solubility decreases as pH increases; drugs that increase gastric pH are expected to decrease levels of ledipasvir; separate antacid and ledipasivr/sofosbuvir administration by 4 hr.
- levofloxacin
magnesium oxide decreases levels of levofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- lisdexamfetamine
magnesium oxide will increase the level or effect of lisdexamfetamine by passive renal tubular reabsorption - basic urine. Use Caution/Monitor.
- methylphenidate
magnesium oxide decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided.
- moxifloxacin
magnesium oxide decreases levels of moxifloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- neratinib
magnesium oxide will decrease the level or effect of neratinib by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Separate antacid and neratinib dosing by 3 hr.
- nilotinib
magnesium oxide decreases levels of nilotinib by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Avoid this interaction by administering antacids 2 hr after or 2 hr before nilotinib.
- ofloxacin
magnesium oxide decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- omadacycline
magnesium oxide will decrease the level or effect of omadacycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.
- penicillamine
magnesium oxide decreases levels of penicillamine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- pexidartinib
magnesium oxide will decrease the level or effect of pexidartinib by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Separate pexidartinib by 2 hr before or after taking a locally-acting antacid.
- rilpivirine
magnesium oxide decreases levels of rilpivirine by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Coadministration of antacids with rilpivirine may cause significant decreases in rilpivirine plasma concentrations because of increased gastric pH. If antacids must be administered, they should be given at least 2 hr before or at least 4 hr after rilpivirine. For the combination product dolutegravir/rilpivirine, antacids should be given at least 4 hr before or at least 6 hr afterwards.
- riociguat
magnesium oxide decreases levels of riociguat by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate administration by at least 1 hour.
- sarecycline
magnesium oxide will decrease the level or effect of sarecycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.
- sodium sulfate/?magnesium sulfate/potassium chloride
sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of magnesium oxide by Other (see comment). Use Caution/Monitor. Comment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.
- sodium sulfate/potassium sulfate/magnesium sulfate
sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of magnesium oxide by Other (see comment). Use Caution/Monitor. Comment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.
- sofosbuvir/velpatasvir
magnesium oxide will decrease the level or effect of sofosbuvir/velpatasvir by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Velpatasvir solubility decreases as gastric pH increases (practically insoluble at pH >5). Separate administration of sofosbuvir/velpatasvir from antacids by at least 4 hr.
- sparsentan
magnesium oxide decreases effects of sparsentan by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer sparsentan 2 hours before or after administration of antacids. Antacids may decrease sparsentan exposure which may reduce efficacy of sparsentan.
- vismodegib
magnesium oxide will decrease the level or effect of vismodegib by Other (see comment). Use Caution/Monitor. Drugs that increase gastric pH alter vismodegib solubility and therefore reduce bioavailability; effect on efficacy unknown
Minor (40)
- amikacin
amikacin decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- amiloride
amiloride increases levels of magnesium oxide by decreasing renal clearance. Minor/Significance Unknown.
- amphotericin B deoxycholate
amphotericin B deoxycholate decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- bazedoxifene/conjugated estrogens
bazedoxifene/conjugated estrogens decreases levels of magnesium oxide by Other (see comment). Minor/Significance Unknown. Comment: Magnesium shifted from blood to tissue storage.
- bendroflumethiazide
bendroflumethiazide decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- bumetanide
bumetanide decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- calcitonin salmon
calcitonin salmon increases levels of magnesium oxide by decreasing renal clearance. Minor/Significance Unknown.
- chlorothiazide
chlorothiazide decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- chlorthalidone
chlorthalidone decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- cisplatin
cisplatin decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- conjugated estrogens
conjugated estrogens decreases levels of magnesium oxide by Other (see comment). Minor/Significance Unknown. Comment: Magnesium shifted from blood to tissue storage.
- conjugated estrogens, vaginal
conjugated estrogens, vaginal decreases levels of magnesium oxide by Other (see comment). Minor/Significance Unknown. Comment: Magnesium shifted from blood to tissue storage.
- cyclopenthiazide
cyclopenthiazide decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- dextrose
dextrose decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- digoxin
digoxin decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- doxercalciferol
doxercalciferol increases levels of magnesium oxide by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- drospirenone
drospirenone increases levels of magnesium oxide by decreasing renal clearance. Minor/Significance Unknown.
- estradiol
estradiol decreases levels of magnesium oxide by Other (see comment). Minor/Significance Unknown. Comment: Magnesium shifted from blood to tissue storage.
- estrogens conjugated synthetic
estrogens conjugated synthetic decreases levels of magnesium oxide by Other (see comment). Minor/Significance Unknown. Comment: Magnesium shifted from blood to tissue storage.
- estrogens esterified
estrogens esterified decreases levels of magnesium oxide by Other (see comment). Minor/Significance Unknown. Comment: Magnesium shifted from blood to tissue storage.
- estropipate
estropipate decreases levels of magnesium oxide by Other (see comment). Minor/Significance Unknown. Comment: Magnesium shifted from blood to tissue storage.
- ethacrynic acid
ethacrynic acid decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- furosemide
furosemide decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- gentamicin
gentamicin decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- glucagon intranasal
glucagon intranasal increases levels of magnesium oxide by decreasing renal clearance. Minor/Significance Unknown.
- hydrochlorothiazide
hydrochlorothiazide decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- ibandronate
magnesium oxide decreases levels of ibandronate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- indapamide
indapamide decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- mannitol
mannitol decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- mestranol
mestranol decreases levels of magnesium oxide by Other (see comment). Minor/Significance Unknown. Comment: Magnesium shifted from blood to tissue storage.
- metolazone
metolazone decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- neomycin PO
neomycin PO decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- nitrofurantoin
magnesium oxide decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- paromomycin
paromomycin decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- sodium polystyrene sulfonate
sodium polystyrene sulfonate increases levels of magnesium oxide by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis.
- spironolactone
spironolactone increases levels of magnesium oxide by decreasing renal clearance. Minor/Significance Unknown.
- streptomycin
streptomycin decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- tobramycin
tobramycin decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- torsemide
torsemide decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.
- triamterene
triamterene increases levels of magnesium oxide by decreasing renal clearance. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
Diarrhea with excessive dose
Gastrointestinal irritation
Warnings
Contraindications
Hypersensitivity
Cautions
Normal serum magnesium ~1.5-2.5 mg/dL
Laxative effect
Magnesium supplementation may exacerbate
Caution with renal impairment
Caution with myasthenia gravis or other neuromuscular diseases
Pregnancy & Lactation
Pregnancy Category: A; 350-400 mg/day elemental Mg recommended during pregnancy
Lactation: Distributed in breast milk; 310-360 mg/day elemental Mg recommended during lactation
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Mineral; cofactor in many enzymatic reactions and essential for various metabolic functions (eg, phosphate transfer, muscle contraction, nerve conduction)
Pharmacokinetics
Absorption: Inversely proportional to dose; ~50% with controlled dietary intake, compared with 15-30% with high dose
Distribution sites: 50-60% (bone); 1-2% (extracellular fluid)
Protein Bound: 30% (albumin)
Excretion: Urine
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  | |
| magnesium oxide oral - | 250 mg magnesium tablet |  | |
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  | |
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  | |
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  | |
| magnesium oxide oral - | 240 mg magnesium powder |  | |
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  | |
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  | |
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  | |
| magnesium oxide oral - | 500 mg capsule |  | |
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  | |
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  | |
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  | |
| magnesium oxide oral - | 250 mg magnesium tablet |  | |
| magnesium oxide oral - | 250 mg magnesium tablet |  | |
| magnesium oxide oral - | 420 mg tablet |  | |
| magnesium oxide oral - | 500 mg tablet |  | |
| magnesium oxide oral - | 400 mg magnesium tablet |  | |
| magnesium oxide oral - | 250 mg magnesium tablet |  | |
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  | |
| magnesium oxide oral - | 400 mg magnesium capsule |  | |
| magnesium oxide oral - | 250 mg magnesium tablet |  | |
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  | |
| magnesium oxide oral - | 250 mg magnesium tablet |  | |
| magnesium oxide oral - | 400 mg (241.3 mg magnesium) tablet |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
magnesium oxide oral
MAGNESIUM SUPPLEMENT - ORAL
(mag-NEE-zee-um)
COMMON BRAND NAME(S): Uro-Mag
USES: This medication is a mineral supplement used to prevent and treat low amounts of magnesium in the blood. Some brands are also used to treat symptoms of too much stomach acid such as stomach upset, heartburn, and acid indigestion. Magnesium is very important for the normal functioning of cells, nerves, muscles, bones, and the heart. Usually, a well-balanced diet provides normal blood levels of magnesium. However, certain situations cause your body to lose magnesium faster than you can replace it from your diet. These situations include treatment with "water pills" (diuretics such as furosemide, hydrochlorothiazide), a poor diet, alcoholism, or other medical conditions (such as severe diarrhea/vomiting, stomach/intestinal absorption problems, poorly controlled diabetes).
HOW TO USE: Take this product by mouth as directed. Follow all directions on the product package. If you have any questions, ask your doctor or pharmacist.It is best to take magnesium supplements with a meal to reduce stomach upset and diarrhea unless otherwise directed by the product instructions or your doctor.Take each dose with a full glass (8 ounces or 240 milliliters) of water unless your doctor directs you otherwise. Swallow extended-release capsules and delayed-release/enteric coated tablets or capsules whole. Do not crush or chew extended-release or delayed-release/enteric coated capsules or tablets. Doing so can release all of the drug at once, increasing the risk of side effects. Also, do not split extended-release tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.If you are taking the chewable tablets, chew each tablet thoroughly before swallowing.If you are using a liquid product, use a medication measuring device to carefully measure the dose. Do not use a household spoon because you may not get the correct dose. If you are using a suspension, shake the bottle well before each dose.Take this medication regularly in order to get the most benefit from it. Remember to take it at the same time(s) each day. Dosage is based on your medical condition and response to treatment. Do not increase your dose or take it more often than directed on the product package or by your doctor. Too much magnesium in the blood can cause serious side effects.Tell your doctor if symptoms of low magnesium blood levels (such as muscle cramps, tiredness, irritability, depression) last or get worse. If you think you may have a serious medical problem, get medical help right away.
SIDE EFFECTS: Stomach upset and diarrhea may occur. Taking this product with a meal helps to reduce these effects. If either of these effects last or get worse, tell your doctor or pharmacist promptly.If your doctor has directed you to use this medication, remember that your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking a magnesium supplement, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.If you have the following health problem, consult your doctor or pharmacist before using this product: kidney disease.Liquids, powders, or some other forms of this product may contain sugar and/or aspartame. Liquid products may also contain alcohol. Caution is advised if you have diabetes, alcohol dependence, liver disease, phenylketonuria (PKU), or any other condition that requires you to limit/avoid these substances in your diet. Ask your doctor or pharmacist about using this product safely.During pregnancy, this product should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this product passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug are: cellulose sodium phosphate, digoxin, sodium polystyrene sulfonate.Magnesium can bind with certain medications, preventing their full absorption. If you are taking a tetracycline-type medication (such as demeclocycline, doxycycline, minocycline, tetracycline), separate the time of the dose from the time of the magnesium supplement dose by at least 2 to 3 hours. If you are taking a bisphosphonate (for example, alendronate), a thyroid medication (for example, levothyroxine), or a quinolone-type antibiotic (such as ciprofloxacin, levofloxacin), ask your doctor or pharmacist about how long you should wait between doses and for help finding a dosing schedule that will work with all your medications.Check the labels on all your prescription and nonprescription/herbal products (such as antacids, laxatives, vitamins) because they may contain magnesium. Ask your pharmacist about using those products safely.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include slow heartbeat, severe drowsiness, dizziness, confusion, muscle weakness, loss of consciousness.
NOTES: Lab and/or medical tests (such as magnesium blood levels, kidney function) should be done while you are taking this medication. Keep all medical and lab appointments. Consult your doctor for more details.Magnesium supplements are available in different forms with different amounts of magnesium. Many are available without a prescription. Ask your doctor or pharmacist for help in selecting the best product for you.Eat a well-balanced diet. Foods high in magnesium include avocados, bananas, beans, whole grain cereals, green vegetables, and nuts.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised May 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
